Sacubitril / valsartan (new indication: chronic heart failure with left ventricular systolic dysfunction for patients aged ≥ 1 year)

Subject:

• Active Substance: Sacubitril / valsartan
• Name: Entresto®
• Therapeutic area: Heart failure
• Pharmaceutical company: Novartis Pharma GmbH 

Time table:

• Start: 15.06.2023
• Publication of assessment: 15.09.2023
• End of public hearing: 06.10.2023
• Final decision by G-BA: beginning of December 2023

Comparative therapy:

• Best supportive care